Respiratory Syncytial Virus (RSV) Therapeutics Market Report 2026

The respiratory syncytial virus (rsv) therapeutics market size has grown exponentially in recent years. It will grow from $2 billion in 2025 to $2.46 billion in 2026 at a compound annual growth rate (CAGR) of 23.2%. The growth in the historic period can be attributed to increasing rsv-related hospitalization rates, reliance on supportive care treatments, early adoption of palivizumab therapy, growing pediatric healthcare expenditure, expanding hospital-based treatment access.

The respiratory syncytial virus (rsv) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $5.63 billion in 2030 at a compound annual growth rate (CAGR) of 23%. The growth in the forecast period can be attributed to increasing investments in rsv vaccine and drug development, rising focus on long-acting antibodies, growing demand for pediatric antiviral therapies, expansion of outpatient treatment options, increasing regulatory approvals for novel rsv drugs. Major trends in the forecast period include increasing development of monoclonal antibody therapies, rising focus on antiviral drug innovation, growing adoption of immune prophylaxis treatments, expansion of pediatric-specific rsv therapies, enhanced focus on long-acting preventive drugs.

The increasing prevalence of respiratory syncytial virus (RSV) infections is anticipated to drive the growth of the RSV therapeutics market in the coming years. RSV is a common respiratory virus that can cause mild to severe respiratory illness, particularly affecting newborns, young children, older adults, and individuals with weakened immune systems. The rising incidence of RSV infections is accelerating the development of innovative therapeutic options to meet growing clinical demand and reduce the severity of RSV-related complications. For example, in September 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, RSV-associated hospitalization rates among children under four years of age increased significantly, rising from 2 hospitalizations per 100,000 population for the week ending August 5, 2023, to 7 hospitalizations per 100,000 population by August 19, 2023. Therefore, the growing prevalence of RSV infections is fueling the expansion of the respiratory syncytial virus (RSV) therapeutics market.

Major companies operating in the respiratory syncytial virus (RSV) therapeutics market are focusing on the development of innovative therapies, such as next-generation prefusion F-protein vaccines, to enhance immune protection and reduce the risk of severe RSV-related disease. These advanced vaccines are engineered using stabilized prefusion F-protein antigens designed to elicit stronger and more targeted immune responses compared to traditional vaccine formulations. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical manufacturer, received approval from the US Food and Drug Administration (FDA) for ABRYSVO, a bivalent RSV prefusion F (RSVpreF) vaccine. ABRYSVO is indicated for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 years and older. The unadjuvanted vaccine contains two prefusion F proteins optimized to provide immunity against both RSV A and RSV B strains and has demonstrated safety and effectiveness in clinical studies.

In June 2023, Meissa Vaccines, a US-based clinical-stage biotechnology company, entered into a current Good Manufacturing Practice (cGMP) manufacturing partnership with Exothera S.A. to support the production of its pediatric RSV vaccine candidate for Phase 2 clinical trials. Through this collaboration, Meissa aims to ensure scalable, regulatory-compliant manufacturing capacity to advance its MV-012-968 RSV vaccine program into later-stage development. Exothera S.A. is a Belgium-based company specializing in process development, viral vector manufacturing, and large-scale cGMP production services for vaccine and cell and gene therapy developers.

Major companies operating in the respiratory syncytial virus (rsv) therapeutics market are F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline plc, Gilead Sciences Inc, Moderna Inc, Regeneron Pharmaceuticals Inc, Novavax AB, Vir Biotechnology Inc, Enanta Pharmaceuticals Inc, Kyorin Pharmaceutical Co Ltd, Bavarian Nordic A S, Lupin Limited, Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc, Ascletis Pharma Inc, NanoBio Corporation, Vaxart Inc, Ark Biosciences Private Limited, Pulmocide Ltd, Pfizer Inc, Takeda Pharmaceutical Company Limited.

North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (rsv) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the respiratory syncytial virus (rsv) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the RSV therapeutics market by increasing costs of imported active pharmaceutical ingredients, biologics manufacturing inputs, sterile packaging materials, and cold-chain logistics equipment. Pharmaceutical manufacturing hubs in North America and Europe are most affected due to cross-border dependency on biologics supply chains, while Asia-Pacific faces higher export-related cost pressures. These tariffs are elevating treatment costs and impacting hospital procurement budgets. However, they are also driving local biologics manufacturing investments, regional API production, and stronger domestic pharmaceutical supply chains for RSV therapeutics.

The respiratory syncytial virus (rsv) therapeutics market research report is one of a series of new reports that provides respiratory syncytial virus (rsv) therapeutics market statistics, including respiratory syncytial virus (rsv) therapeutics industry global market size, regional shares, competitors with a respiratory syncytial virus (rsv) therapeutics market share, detailed respiratory syncytial virus (rsv) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus (rsv) therapeutics industry. This respiratory syncytial virus (rsv) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory syncytial virus (RSV) therapeutics refers to the treatments and medications used to manage and treat infections caused by the respiratory syncytial virus. RSV is a common respiratory virus that can lead to mild to severe respiratory illness, particularly in infants, young children, older adults, and individuals with weakened immune systems.

The main types of drugs used in respiratory syncytial virus (RSV) therapeutics include palivizumab, ribavirin, and others. Palivizumab is a monoclonal antibody developed using recombinant DNA technology for respiratory infections and is used in children to prevent serious complications associated with RSV infection. These treatments are categorized into immune prophylaxis, supportive care, and antiviral therapies, and are administered in dosage forms such as oral, injectable, and others for patient groups including pediatrics and adults. Distribution channels for these therapeutics include hospital pharmacies, retail pharmacies, and online pharmacies.

The respiratory syncytial virus (RSV) therapeutics market includes revenues earned by entities by providing services such as home care and respiratory support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The respiratory syncytial virus (RSV) therapeutics market consists of sales of antiviral drugs, monoclonal antibodies, and vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.